EPO and cancer: In 2003, two studies found that patients with metastatic breast cancer and patients with head and neck cancer who received recombinant human EPO (rHuEPO) in combination with chemotherapy or radiation therapy to manage cancer-associated anemia exhibited higher mortality compared with patient groups who received a placebo22,23.